1.
Clin Pharmacol Ther
; 111(4): 835-839, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35234294
RESUMO
Use of early predictive biomarkers of neurodegenerative disease in phase I clinical trials may improve the translation of novel drug therapies from preclinical development through late-stage studies. This article provides a categorical summary of promising biomarker approaches or clinical end points in molecular, cellular, metabolic, electrophysiological, or clinical function that can be used to predict or quantify the progression of neurodegenerative disorders and guide program support.